KUALA LUMPUR, July 30 (Bernama) -- Bursa Malaysia's key index closed at an intraday high today, supported by continued buying interest even as renewed geopolitical tensions and a weaker overnight lead from Wall Street following the US Federal Reserve's (Fed) decision to stand pat on interest rates weighed on broader sentiment. The Fed has decided to hold rates steady for the fifth consecutive meeting, with the Federal Funds Rate unchanged between 3.50 per cent and 3.75 per cent. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) rose 4.84 points to 1,720.40 from yesterday’s close of 1,715.56. The benchmark index, which opened 1.14 points lower at 1,714.42, hit its lowest level of 1,710.69 in early trade before gaining momentum for the rest of the day. However, the broader market was negative with losers outpacing gainers 581 to 411, while 612 counters were unchanged, 1,173 untraded, and 87 suspended. Turnover declined to 2.49 billion units valued at RM2.25 billion from ...
Tempus AI Inc. (NASDAQ: TEM) continues to draw strong interest from institutional investors, with Cathie Wood’s ARK Invest adding to its position in the precision health tech company.
In its latest move, ARK Investment Management purchased 150,563 shares, valued at approximately US$8.8 million. The majority were acquired through the flagship ARK Innovation ETF (ARKK), with a smaller tranche via the ARK Genomic Revolution ETF (ARKG) — signaling continued conviction in Tempus’ AI-driven healthcare model. A separate US$1 million worth of shares was also added, highlighting ARK's sustained bullish stance.
Strategic Expansion in Cancer Detection
Tempus has recently expanded its collaboration with Personalis Inc. to include colorectal cancer, alongside existing work in breast, lung, and immunotherapy monitoring.
This bolsters the commercialization of the NeXT Personal™ MRD (Minimal Residual Disease) assay, a powerful tool for detecting cancer recurrence and monitoring treatment response across four major oncology indications.
The strategic alignment strengthens Tempus’ leadership in AI-powered diagnostics and precision oncology — a rapidly growing sector at the intersection of genomics, data science, and personalized medicine.
Stock Performance & Analyst Outlook
YTD Performance: +76.54%
Last Traded Price: US$59.60
12-Month Target Price (Consensus): US$66.70
Analyst Ratings: 7 Buys, 6 Holds (Bloomberg consensus)
Comments
Post a Comment